公开(公告)号：US20110038869A1

公开(公告)日：2011-02-17

申请号：US12811637

申请日：2008-12-19

Applicant: Edward Norbert Van Den Brink ,  Paul Parren ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Frank Everhardus Martinus Rebers ,  Esther Cornelia Wilhelmina Breij

Inventor： Edward Norbert Van Den Brink ,  Paul Parren ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Frank Everhardus Martinus Rebers ,  Esther Cornelia Wilhelmina Breij

IPC: A61K39/395 ,  C07K16/18 ,  C12P21/08 ,  C12N15/63 ,  C12N5/10 ,  C12N1/00 ,  C12N5/16 ,  G01N33/574 ,  C07K16/42 ,  A61P35/00 ,  A61P11/06 ,  A61P37/04 ,  A61P37/06

CPC classification number: C07K16/283 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human CD32b and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了与人CD32b和相关的基于抗体的组合物和分子结合的分离的单克隆抗体。 还公开了包含抗体的药物组合物，以及使用抗体的治疗和诊断方法。

公开(公告)号：US20100015644A1

公开(公告)日：2010-01-21

申请号：US11989064

申请日：2006-07-21

Applicant: Catharina Emanuele Gerarda Havenith ,  Tom Vink ,  Van Berkel Patrick ,  Paul Parren

Inventor： Catharina Emanuele Gerarda Havenith ,  Tom Vink ,  Van Berkel Patrick ,  Paul Parren

IPC: G01N33/53 ,  G01N33/566 ,  C07K16/18 ,  C12M1/22

CPC classification number: C07K16/2812 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/566 ,  G01N2333/70535

Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

Abstract translation: 本发明涉及一种表征抗体的方法，该方法适用于批量释放包含抗体的药物组合物的效力测定，该抗体特别用于在申请所述药物组合物的营销授权时使用。 提供的测定法是用于测定包含FcR结合肽的药物产品的效力的方法，其中药物产物的FcR结合肽的至少一种作用机制是通过药物产物的FcR结合肽的结合来介导的 其中所述方法包括测定药物产物的FcR结合肽与Fc受体的结合。

公开(公告)号：US20090148449A1

公开(公告)日：2009-06-11

申请号：US11886932

申请日：2006-03-23

Applicant: Michel De Weers ,  Yvo Graus ,  Judith Oprins ,  Paul Parren ,  Jan Van De Winkel ,  Martine Van Vugt

Inventor： Michel De Weers ,  Yvo Graus ,  Judith Oprins ,  Paul Parren ,  Jan Van De Winkel ,  Martine Van Vugt

IPC: A61K39/395 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  C12N5/06 ,  G01N33/574 ,  A61K31/7088 ,  C12N1/21 ,  A01K67/027 ,  A01H5/00

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0004 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/566 ,  G01N2333/70596

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人CD38结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 还公开了包含人抗体的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20090081219A1

公开(公告)日：2009-03-26

申请号：US12283775

申请日：2008-09-16

Applicant: Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G.J. Van De Winkel ,  Denise Leah Williams ,  Jorgen Petersen ,  Ole Baadsgaard

Inventor： Janine Schuurman ,  Catharina Emanuele Gerarda Havenith ,  Paul Parren ,  Jan G.J. Van De Winkel ,  Denise Leah Williams ,  Jorgen Petersen ,  Ole Baadsgaard

IPC: A61K39/395 ,  G01N33/53 ,  A61P37/02 ,  A61P37/08

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/062 ,  C07K16/4258 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/56966 ,  G01N33/57492 ,  G01N33/6854 ,  G01N33/6869 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2333/7155

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD25的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人类转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物，产生人抗体的杂交瘤和转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US07247301B2

公开(公告)日：2007-07-24

申请号：US10172317

申请日：2002-06-13

Applicant: Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Arnout F. Gerritsen ,  Edward Halk

Inventor： Jan G. J. van de Winkel ,  Marcus A. van Dijk ,  Arnout F. Gerritsen ,  Edward Halk

IPC: C07K16/24 ,  C07K16/00 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/732

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人EGFR特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20050123542A1

公开(公告)日：2005-06-09

申请号：US10982725

申请日：2004-11-04

Applicant: Frank Beurskens ,  Janine Schuurman ,  Paul Parren ,  Jorgen Petersen ,  Ole Baadsgaard

Inventor： Frank Beurskens ,  Janine Schuurman ,  Paul Parren ,  Jorgen Petersen ,  Ole Baadsgaard

IPC: C07K16/24 ,  A61K39/395 ,  A61K38/17 ,  A61K38/20

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  Y02A50/41

Abstract: Methods for treating disorders involving monocytic activity by administering IL-15 antagonists that induce apoptosis of monocytes are disclosed.

Abstract translation: 公开了通过施用诱导单核细胞凋亡的IL-15拮抗剂来治疗涉及单核细胞活性的疾病的方法。

公开(公告)号：US20030091561A1

公开(公告)日：2003-05-15

申请号：US10172317

申请日：2002-06-13

Applicant: GENMAB A/S

Inventor： Jan G.J. van de Winkel ,  Marcus A. van Dijk ,  Arnout F. Gerritsen ,  Edward Halk

IPC: A61K039/395 ,  C12N005/06 ,  C07K016/28

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/732

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20240327544A1

公开(公告)日：2024-10-03

申请号：US18579086

申请日：2022-07-13

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Sina FELLERMEIER-KOPF ,  Yali FU ,  Homer ADAMS, III ,  Gaurav BAJAJ ,  Brandon HIGGS ,  Mark FERESHTEH ,  Vanessa SPIRES ,  Jordan BLUM ,  Patricia GARRIDO CASTRO ,  Michelle NIEWOOD ,  Friederike GIESEKE ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Ivan KUZMANOV ,  Esther Cornelia Wilhelmina BREIJ ,  Lars GUELEN ,  Jost NEIJSSEN ,  Bart-Jan DE KREUK ,  Richard HIBBERT ,  Janine SCHUURMAN ,  Aran Frank LABRIJN

IPC: C07K16/46 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/76

Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240317861A1

公开(公告)日：2024-09-26

申请号：US18539509

申请日：2023-12-14

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/4258 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20240254249A1

公开(公告)日：2024-08-01

申请号：US18481578

申请日：2023-10-05

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.